MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months

MAIA Biotechnology, Inc.

Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.
95% CI lower bound of 12.5 months and 99% CI lower bound of 10.8 months shown.
New partial response (>=30% tumor reduction) observed after >20 months on treatment.
Longest-surviving patient reached 24.3 months and completed 32 cycles of therapy.
Potential FDA decision for ateganosine as early as next year.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.